We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+2.93%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$182M
AUM Growth
-$9.72M
(-5.1%)
Cap. Flow
-$9.6M
Cap. Flow
% of AUM
-5.28%
Top 10 Holdings %
Top 10 Hldgs %
6.2%
Holding
508
New
65
Increased
160
Reduced
215
Closed
68
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Dow Inc
DOW
|
+$1.19M |
| 2 |
Progressive
PGR
|
+$963K |
| 3 |
Hershey
HSY
|
+$960K |
| 4 |
DexCom
DXCM
|
+$934K |
| 5 |
Copart
CPRT
|
+$930K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lennar Class A
LEN
|
+$952K |
| 2 |
TJX Companies
TJX
|
+$909K |
| 3 |
Ameriprise Financial
AMP
|
+$902K |
| 4 |
Abbott
ABT
|
+$892K |
| 5 |
Home Depot
HD
|
+$885K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.65% |
| 2 | Financials | 14.09% |
| 3 | Technology | 11.21% |
| 4 | Energy | 10.21% |
| 5 | Materials | 8.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
351
Geron
GERN
$898M
| $93.4K | 0.05% |
43,051
-16,553
| -28% | -$47K |
|
352
Xenon Pharmaceuticals
XENE
$6.1B
| $93.4K | 0.05% |
2,610
-1,006
| -28% | -$37.2K |
|
353
Nuvation Bio
NUVB
$2.29B
| $93.3K | 0.05% |
56,210
-21,606
| -28% | -$43.8K |
|
354
Seres Therapeutics
MCRB
$45M
| $92.7K | 0.05% |
817
-314
| -28% | -$34K |
|
355
Viridian Therapeutics
VRDN
$2.2B
| $92.2K | 0.05% |
3,623
-1,394
| -28% | -$44.7K |
|
|
CERE
356
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $91.7K | 0.05% |
3,760
-1,451
| -28% | -$42.6K |
|
357
Iovance Biotherapeutics
IOVA
$2.04B
| $91.7K | 0.05% |
15,009
-5,773
| -28% | -$39.8K |
|
358
CRISPR Therapeutics
CRSP
$4.69B
| $91.2K | 0.05% |
2,017
-774
| -28% | -$37.6K |
|
|
NBP
359
NovaBridge Biosciences American Depositary Shares
NBP
$186M
| $91.2K | 0.05% |
26,347
-10,129
| -28% | -$49.1K |
|
|
RNAM
360
DELISTED
Avidity Biosciences
RNAM
| $91K | 0.05% |
5,931
-2,284
| -28% | -$50.3K |
|
361
Vir Biotechnology
VIR
$1.46B
| $90.9K | 0.05% |
3,905
-1,503
| -28% | -$38.4K |
|
362
Celldex Therapeutics
CLDX
$2.94B
| $90.4K | 0.05% |
2,513
-967
| -28% | -$41.7K |
|
363
Revolution Medicines
RVMD
$38.5B
| $90.3K | 0.05% |
4,169
-1,602
| -28% | -$39.4K |
|
364
Cogent Biosciences
COGT
$6.76B
| $90.3K | 0.05% |
8,367
-3,209
| -28% | -$41K |
|
|
KRTX
365
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $90.3K | 0.05% |
497
-188
| -27% | -$36K |
|
366
Biohaven
BHVN
$2.02B
| $87.9K | 0.05% |
6,438
-2,478
| -28% | -$39.4K |
|
|
AKRO
367
DELISTED
Akero Therapeutics
AKRO
| $87.6K | 0.05% |
2,289
-875
| -28% | -$39K |
|
368
Zentalis Pharmaceuticals
ZNTL
$332M
| $87.1K | 0.05% |
5,065
-1,945
| -28% | -$39.4K |
|
369
Syndax Pharmaceuticals
SNDX
$1.7B
| $87K | 0.05% |
4,120
-1,581
| -28% | -$39.3K |
|
370
Cullinan Oncology
CGEM
$1.06B
| $86.8K | 0.05% |
8,483
-3,268
| -28% | -$36K |
|
371
uniQure
QURE
$2.78B
| $86.7K | 0.05% |
4,306
-1,649
| -28% | -$34.6K |
|
|
MRTX
372
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $86.2K | 0.05% |
2,318
-885
| -28% | -$39.8K |
|
373
Keros Therapeutics
KROS
$197M
| $86.1K | 0.05% |
2,017
-771
| -28% | -$38.9K |
|
374
Kodiak Sciences
KOD
$2.5B
| $86.1K | 0.05% |
13,880
-5,334
| -28% | -$37.3K |
|
375
Cytokinetics
CYTK
$10.6B
| $86K | 0.05% |
2,445
-938
| -28% | -$38.3K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
RC
Virtus ETF Advisers's Q1 2023 Portfolio in Review
As of Q1 2023, Virtus ETF Advisers held 508 positions worth $182M, down 5.1% from $191M the previous quarter. Its ten largest holdings account for 6.2% of the portfolio.
Virtus ETF Advisers withdrew a net $9.6M in Q1 2023, closing 68 positions and reducing 215 holdings. Its most notable exit was Lennar Class A, an estimated $952K position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 26% of assets, down from 27% a quarter earlier, followed by Financials and Technology.
Against the trend, Virtus ETF Advisers opened a new position in Dow Inc worth $1.16M.
- Virtus ETF Advisers's largest Q1 2023 buy was Dow Inc: 21,099 shares worth $1.16M.
- Virtus ETF Advisers added most to Devon Energy in Q1 2023, an estimated $447K increase.
- Virtus ETF Advisers's biggest Q1 2023 reduction was LyondellBasell Industries, cutting an estimated $514K.
- Virtus ETF Advisers fully exited Lennar Class A in Q1 2023, selling an estimated $952K.
- Virtus ETF Advisers's ten largest holdings make up 6.2% of its $182M portfolio in Q1 2023.
- Virtus ETF Advisers opened 65 new positions and closed 68 in Q1 2023.
- Virtus ETF Advisers's portfolio value fell 5.1% quarter-over-quarter to $182M.
Based on Virtus ETF Advisers's 13F filing for Q1 2023, filed 15 May 2023.